Federally Funded Study Finds Cannabis Reduces Opioid Use, Withdrawal

Study Design and Participant Demographics

The research team surveyed 197 people in Vancouver who reported using both cannabis and unregulated opioids such as fentanyl or heroin. Federal agencies funded the work. Researchers conducted structured interviews with participants recruited from harm-reduction sites and community health centers. The median age was 42 years, with 68% identifying as male and 32% as female. About 71% of the cohort reported daily opioid use at baseline.

The survey asked participants to self-report frequency of opioid consumption, withdrawal severity on a 10-point scale, and patterns of cannabis use over a 90-day observation window. Researchers controlled for variables including housing status, concurrent stimulant use, and participation in medication-assisted treatment programs.

Primary Outcome: Reduced Opioid Consumption

Participants who used cannabis daily reported consuming unregulated opioids on 23% fewer days compared to those who didn't use cannabis. The association held after adjusting for confounders including age, sex, and baseline opioid dependence severity. Among the subset of participants who used cannabis specifically to manage cravings, the reduction in opioid use days climbed to 31%.

The study didn't measure blood levels or toxicology screens. It relied on participant self-report instead. That's a limitation. But the consistency of the signal across multiple subgroups and the dose-response relationship between cannabis frequency and opioid reduction strengthen the finding.

Withdrawal Symptom Mitigation

Participants who used cannabis during opioid withdrawal episodes reported symptom severity scores 2.4 points lower on a 10-point scale compared to withdrawal episodes without cannabis use. The most commonly cited symptoms that improved with cannabis use were nausea, muscle aches, anxiety, and insomnia. Seventy-eight percent of participants who used cannabis during withdrawal said it provided at least moderate relief.

Researchers noted that while cannabis didn't eliminate withdrawal symptoms entirely, the magnitude of relief was comparable to low-dose buprenorphine in prior studies. This aligns with preclinical research showing cannabinoid receptor activation modulates opioid withdrawal pathways in animal models.

The magnitude of withdrawal relief reported by participants who used cannabis was comparable to low-dose buprenorphine in prior studies, suggesting a clinically meaningful effect.

Harm Reduction Context and Policy Implications

The study was conducted in Vancouver, a city with supervised consumption sites and a regulated cannabis market, factors that may limit generalizability to U.S. jurisdictions. Canada's federal cannabis legalization in 2018 and British Columbia's harm-reduction infrastructure create an environment where participants can access both cannabis and sterile injection equipment without criminalization. Context matters when interpreting the results.

For U.S. policymakers, the findings add to a growing body of evidence that cannabis access may complement medication-assisted treatment for opioid use disorder. The study doesn't support cannabis as a standalone replacement for buprenorphine or methadone, which remain the gold standard for opioid dependence treatment. Researchers emphasized that cannabis use should be considered within a broader harm-reduction framework, not as monotherapy.

Limitations and Methodological Notes

The study's reliance on self-reported data and its observational design prevent causal claims. Participants who chose to use cannabis may differ systematically from those who didn't in ways the statistical adjustments couldn't capture. The 90-day recall window introduces potential memory bias, particularly among participants with active substance use disorders. No placebo control or randomization was employed.

The sample was drawn from a single urban center with high rates of fentanyl contamination in the unregulated opioid supply. Whether these findings apply to rural areas or regions where heroin remains the dominant street opioid is unclear. The study also didn't differentiate between smoked, vaporized, and edible cannabis, nor did it measure THC or CBD content of the products used.

What This Means for Clinicians and Patients

The evidence supports discussing cannabis as an adjunctive harm-reduction tool for patients with opioid use disorder, particularly those who aren't candidates for or have failed medication-assisted treatment. Clinicians should ask patients about cannabis use patterns and consider the potential for cannabis to reduce unregulated opioid consumption and withdrawal severity. The data don't support recommending cannabis over buprenorphine or methadone. But they do suggest that cannabis use shouldn't be a disqualifying factor for harm-reduction services.

For full background on this research area, see the CannIntel topic hub on Cannabis and Opioid Harm Reduction. The next major signal to watch: results from two ongoing NIH-funded randomized controlled trials examining cannabinoid formulations as adjuncts to buprenorphine, expected in late 2026 and early 2027.